ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
21.254,38
1,01%
S&P 500
6.049,24
0,88%
Dow Jones
44.025,81
1,24%
Euro vs US Dollar
1,04382
0,31%
Bitcoin
104.756,15
-1,33%
Pepperstone
Advertisement
Registration Strip Icon for alerts Registrieren Sie sich für Echtzeit-Benachrichtigungen, benutzerdefinierte Portfolios und Marktbewegungen.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ

  6. Celldex Therapeutics Inc (CLDX) Börsenkurse

Celldex Therapeutics Inc

Celldex Therapeutics Inc (CLDX)

NASDAQ
24,61
0,83
(3,49%)
Geschlossen 22 Januar 10:00PM
Verzögert um 15 Minuten
24,61
0,00
( 0,00% )
Vor Marktöffnung: 10:00AM
Verzögert um 15 Minuten

Echtzeit-Diskussionen und Handelsideen: Handeln Sie mit Zuversicht mit unserer leistungsstarken Plattform.

Premium

Wichtige Statistiken und Details

Current Price
24,61
Gebot
21,90
Fragen
31,33
Volumen
-
0,00 Tagesbereich 0,00
22,165 52-Wochen-Bereich 53,18
Marktkapitalisierung
1,633B
Handelsende
24,61
Handelsbeginn
-
Letzte Trade
Letzter Handelszeitpunkt
-
Finanzvolumen
-
VWAP
-
Durchschnittliches Volumen (3 Mio.)
1.065.641
Ausgegebene Aktien
66.344.236
Dividendenrendite
-
Kurs-Gewinn-Verhältnis
-11,54
Gewinn pro Aktie (EPS)
-2,13
Erlöse
6,88M
Nettogewinn
-141,43M

Über Celldex Therapeutics Inc

Celldex Therapeutics Inc is a biopharmaceutical company. It is focused on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. The company is also engaged in clinical trials for products targeting breast cancer, metastatic melanoma, lung c... Celldex Therapeutics Inc is a biopharmaceutical company. It is focused on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. The company is also engaged in clinical trials for products targeting breast cancer, metastatic melanoma, lung cancer, solid tumors, and ovarian cancer. Its pipeline products are Varlilumab, CDX-301, CDX-1140,CDX-0159/Anti-KIT Program, and CDX-527. Mehr anzeigen

Sektor
In Vitro,in Vivo Diagnostics
Branche
In Vitro,in Vivo Diagnostics
Website
www.celldex.com
Hauptsitz
Wilmington, Delaware, USA
Gegründet
-
Celldex Therapeutics Inc is listed in the In Vitro,in Vivo Diagnostics sector of the NASDAQ with ticker CLDX. The last closing price for Celldex Therapeutics was US$24,61. Over the last year, Celldex Therapeutics shares have traded in a share price range of US$ 22,165 to US$ 53,18.

Celldex Therapeutics currently has 66.344.236 shares in issue. The market capitalisation of Celldex Therapeutics is US$1,63 billion. Celldex Therapeutics has a price to earnings ratio (PE ratio) of -11.54.

CLDX Neueste Nachrichten

Weitere Nachrichten

Celldex Initiates Phase 2 Study of Barzolvolimab in Atopic Dermatitis

HAMPTON, N.J., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that the Company has initiated a Phase 2 study of barzolvolimab in atopic dermatitis...

19 Dezember 2024
GlobeNewswire Inc.

Form 4 - Statement of changes in beneficial ownership of securities

20 November 2024
Edgar (US Regulatory)

Celldex Announces First Patient Dosed in Phase 1 Healthy Volunteer Study of CDX-622, a Bispecific Antibody, for the Treatment of Inflammatory Diseases

HAMPTON, N.J., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that the first patient has been dosed in the Company’s Phase 1a study of CDX-622 in...

20 November 2024
GlobeNewswire Inc.

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

15 November 2024
Edgar (US Regulatory)

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

14 November 2024
Edgar (US Regulatory)

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

14 November 2024
Edgar (US Regulatory)

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

14 November 2024
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

12 November 2024
Edgar (US Regulatory)

Celldex Therapeutics to Present at Upcoming Investor Conferences

HAMPTON, N.J., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that management will participate in fireside chats at two upcoming conferences:...

11 November 2024
GlobeNewswire Inc.

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

08 November 2024
Edgar (US Regulatory)
Zeitraum †ÄnderungÄnderung %HandelsbeginnHochNiedrigDurchsch. VolumenVWAP
11.014.2796610169523.624.9122.165103327723.32964367CS
4-0.27-1.0852090032224.8829.00722.165107788125.0432304CS
12-2.345-8.6996846596226.95529.00722.165106564125.79982672CS
26-12.61-33.879634605137.224722.165102903431.1338515CS
52-15.47-38.597804391240.0853.1822.16590988435.2392517CS
156-2.66-9.7543087642127.2753.1819.8570015433.68249934CS
26022.28956.2231759662.3357.21.576990027.04159187CS

CLDX - Frequently Asked Questions (FAQ)

What is the current Celldex Therapeutics share price?
The current share price of Celldex Therapeutics is US$ 24,61
How many Celldex Therapeutics shares are in issue?
Celldex Therapeutics has 66.344.236 shares in issue
What is the market cap of Celldex Therapeutics?
The market capitalisation of Celldex Therapeutics is USD 1,63B
What is the 1 year trading range for Celldex Therapeutics share price?
Celldex Therapeutics has traded in the range of US$ 22,165 to US$ 53,18 during the past year
What is the PE ratio of Celldex Therapeutics?
The price to earnings ratio of Celldex Therapeutics is -11,54
What is the cash to sales ratio of Celldex Therapeutics?
The cash to sales ratio of Celldex Therapeutics is 237,32
What is the reporting currency for Celldex Therapeutics?
Celldex Therapeutics reports financial results in USD
What is the latest annual turnover for Celldex Therapeutics?
The latest annual turnover of Celldex Therapeutics is USD 6,88M
What is the latest annual profit for Celldex Therapeutics?
The latest annual profit of Celldex Therapeutics is USD -141,43M
What is the registered address of Celldex Therapeutics?
The registered address for Celldex Therapeutics is 1209 ORANGE STREET, WILMINGTON, DELAWARE, 19801
What is the Celldex Therapeutics website address?
The website address for Celldex Therapeutics is www.celldex.com
Which industry sector does Celldex Therapeutics operate in?
Celldex Therapeutics operates in the IN VITRO,IN VIVO DIAGNOSTICS sector

Beweger

Alle Anzeigen
  • Volumen
  • % Tops
  • % Flops
SymbolPreisVol.
IPAImmunoPrecise Antibodies Ltd
US$ 0,7668
(55,54%)
11,88M
DXRDaxor Corporation
US$ 11,88
(44,56%)
8
NEHCNew Era Helium Inc
US$ 3,95
(44,16%)
1,49M
ADAGAdagene Inc
US$ 2,50
(41,08%)
3
ASSTAsset Entities Inc
US$ 1,23
(36,67%)
8,15M
ABLAbacus Life Inc
US$ 3,01
(-59,97%)
31
RMBIRichmond Mutual Bancorporation Inc
US$ 8,01
(-40,31%)
1
IZTCInvizyne Technologies Inc
US$ 7,02
(-37,88%)
7
GLACGlobal Lights Acquisition Corporation
US$ 7,30
(-31,78%)
6
ARTVArtiva Biotherapeutics Inc
US$ 5,31
(-24,89%)
2
IPAImmunoPrecise Antibodies Ltd
US$ 0,7668
(55,54%)
11,88M
CDIOCardio Diagnostics Holdings Inc
US$ 0,8157
(34,16%)
8,25M
ASSTAsset Entities Inc
US$ 1,23
(36,67%)
8,15M
RIMEAlgorhythm Holdings Inc
US$ 0,038
(9,83%)
7,08M
SHViShares Short Treasury Bond ETF
US$ 110,365
(0,01%)
3,56M

Foren

Foren anzeigen
Keine Diskussionen Gefunden.
Neuen Thread Erstellen

Kürzlich von Ihnen besucht

NASDAQ
CLDX
Celldex Therapeutics
USOTC
BRTHY
Brother Industries (PK)
BIT
Q00295
Leonteq Securities
BIT
GS0111
Goldman Sachs
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2025 ADVFN PLC - Alle Rechte vorbehalten